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SUMMARY
Objective: To determine the prevalence of cardiovascular risk in patients undergoing 
liver transplantation according to the Framingham score, and to evaluate possible as-
sociations with traditional and non-traditional risk factors.  Methods: Cross-sectional 
study in which patients undergoing liver transplantation were stratified by cardiovascu-
lar risk according to the Framingham score. Demographic, socioeconomic, clinical, and 
anthropometric variables were collected to assess the association with cardiovascular 
risk factors using univariate and multivariate statistical analyses. Results: A total of 115 
patients were evaluated, of which 46.1% showed medium or high risk for the occur-
rence of cardiovascular events over ten years. The mean percentage risk of evaluated 
patients was of 9.5 ± 7.8%. Male gender (OR: 4.97; CI: 1.92-12.85; p < 0.01), older age 
(OR: 1,09; CI: 1.04-1.13; p < 0.01), and higher BMI at the moment of assessment (1.09; 
CI: 0.99-1.20; p = 0.03) were factors associated with medium and high cardiovascular 
risk. A higher percentage of cardiovascular risk was also associated with cyclosporine 
use (p = 0.01). Conclusion: The probability of occurrence of cardiovascular events in the 
assessed patients undergoing liver transplantation was higher than that in the Brazilian 
population. Special attention should be paid to this population, especially in relation to 
potentially modifiable factors associated to higher BMI and cyclosporine use. 
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INTRODUCTION
Liver transplantation is the treatment of choice for patients 
with irreversible acute or chronic liver failure. The com-
bination of advances in surgical technique, patient selec-
tion, better perioperative care, and adequate availability 
of immunosuppressive agents has resulted in significant 
improvement in the overall survival aftertransplantation1. 
Currently, almost 90% of patients survive one year after 
the transplantation2, and up to 75% survive after 5 years3.  
However, the increased survival of patients undergoing 
liver transplantation has been accompanied by increased 
prevalence of chronic diseases, usually higher than that 
found in the general population4. Obesity, diabetes mel-
litus, arterial hypertension, dyslipidemia and metabolic 
syndrome are widely diagnosed in these patients5-6; con-
sequently, the incidence of cardiovascular disease has also 
been increasingly described in this population7. Cardio-
vascular disease has been identified as the third leading 
cause of death after liver transplantation8. Some authors 
demonstrated that the risk of ischemic cardiac events and 
cardiovascular death are respectively 3.07 and 2.56 times 
higher in recipients of liver graft compared to age-matched 
population not submitted to transplantation9.  
The immunosuppressive agents used in the post-
transplantation (usually tacrolimus or cyclosporine, and 
prednisone – at least in the early stages), although broadly 
described as responsible for the increase in cardiovascu-
lar risk10, have not always shown that association9,11. While 
much attention has been devoted to the study of immu-
nosuppressive drugs associated with chronic diseases such 
as those present in these patients, few risk factors, except 
these, have been studied, and to date, the cardiovascular 
risk in the Brazilian population referred for liver trans-
plantation is still unknown.
The present study aimed to determine the prevalence 
of cardiovascular risk in patients undergoing liver trans-
plantation according to the Framingham score, and to 
evaluate possible associations with other variables not in-
cluded in this score. 
METHODS
This is a cross-sectional study in which cardiovascular risk 
according to Framingham score was evaluated in patients 
undergoing liver transplantation followed at the outpatient 
clinic of transplantation of the Instituto Alfa de Gastroen-
terologia, Hospital das Clínicas, Universidade Federal of 
Minas Gerais (Belo Horizonte – MG). Data were collected 
from March to October 2008. Patients who underwent 
liver transplantation and were at least 18 years of age were 
included in the study. Pregnant women and patients with 
ascites were excluded from the sample, as these conditions 
would hinder the identification of patients with abdominal 
obesity. Likewise, patients with time of transplantation of 
less than one year were not included, as they often have 
new and transient metabolic disorders as a result of graft 
implantation and high doses of immunosuppressants. 
The study was approved by the Ethics Committee of the 
Universidade Federal de Minas Gerais under protocol 
No. ETIC 44/08. 
The patients were approached and asked about their 
interest in participating in the study while waiting for 
medical consultation at the clinic. After signing the in-
formed consent, a questionnaire was applied covering de-
mographic, socioeconomic, lifestyle, clinical and anthro-
pometric data.
Demographic and socioeconomic data included age, 
gender, marital status, paid professional activity, educa-
tion, and income. Variables related to lifestyle consisted of 
usual hours of sleep per night, smoking and former smok-
ing status, and physical activity level.
Patients were asked about daily physical activities and 
the corresponding responses were transformed into meta-
bolic equivalent tasks (METs)12. The daily activities trans-
formed in METs were multiplied by the respective time 
spent, expressed as fractions of the hour; the results were 
summed and then divided by 24 hours. This value was 
categorized according to the level of activity performed 
(< 1.3: sedentary, 1.3 to 1.5: little active, 1.5 to 1.8: active, 
> 1.9: very active)13 . 
Clinical data included indication for transplantation; 
time of use and cumulative dose of corticosteroids after 
transplantation; use of tacrolimus or cyclosporine; hyper-
tension prior to transplantation and at the time of the in-
terview; diabetes mellitus prior to transplantation and at 
the time of the interview; excess weight and obesity prior 
to liver disease (based on the weight reported by the pa-
tient during the interview); family history of hypertension, 
diabetes mellitus, overweight, and cardiovascular disease. 
Anthropometric data consisted of weight, height, body 
mass index (BMI), waist circumference (WC), hip circum-
ference (HC), and waist-to-hip ratio (WHR). BMI was 
calculated by dividing weight (kg) by height squared (m2), 
and patients were classified as overweight (BMI ≥ 25 kg/m2) 
or obese (BMI ≥ 30 kg/m2)14. The WC measurement (two 
fingers above the umbilicus) was classified as indicative of 
abdominal obesity according to the definitions of the World 
Health Organization (≥ 88 cm for women and ≥ 102 cm 
for men)14 and of the International Diabetes Federation 
(IDF) (≥ 80 cm and ≥ 90 cm, respectively)15.
The Framingham risk score was calculated and strati-
fied according to gender, age, total cholesterol (TC), high 
density lipoprotein (HDL), smoking, systolic blood pres-
sure (SBP), and diastolic blood pressure (DBP). 
Patients were classified into groups according to car-
diovascular risk consistent with the obtained score (< 10%, 
low risk, 10% to 20%, medium risk, ≥ 20%, high risk), and 
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Categorical variables % n
Marital status – married 32.2 37
Unemployed/retired/on leave/homemaker 63.5 73
Physical activity level    
Active 7.0 8
Low active 27.8 32
Sedentary 65.2 75
Smoker 13.0 15
Former smoker 39.3 39
Use of tacrolimus 88.7 102
Use of cyclosporine 11.3 13
Arterial hypertension before transplantation 19.1 22
Current arterial hypertension 38.3 44
Diabetes mellitus before transplantation 5.3 6
Current diabetes mellitus 22.6 26
Numerical variables Mean/median ± Standard deviation/minimum-maximum
Income per capita (R$) 415 83-6.000
Hours of sleep (per day) 7.6 ± 1.3
Physical activity factor (MET/24) 1.35 ± 0.16
Glucose (mg/dL) 97 68-346
Total cholesterol (mg/dL) 166.2 ± 43.2
HDL (mg/dL) 44 21-99
Triglycerides (mg/dL) 124 28-659
Systolic arterial pressure (mmHg) 120 90-180
Table 1 – Demographic, socioeconomic, lifestyle, and clinical data of patients submitted to liver transplantation, Belo 
Horizonte, MG, Brazil, 2011
by clinical manifestations of atherosclerotic disease or 
equivalent, such as the presence of diabetes mellitus type 1 
or type 2 (such individuals show risk > 20% of new cardio-
vascular events over 10 years)16. 
Statistical analyses were performed using the Statisti-
cal Package for Social Sciences (SPSS) for Windows (ver-
sion 17.0), adopting a statistical significance level of 5%. 
The variables are shown as mean and standard deviation, 
and variables with non-normal distribution are shown as 
median, minimum, and maximum values (Kolmogorov-
Smirnov test). 
Patients with medium (10%-20%) and high risk 
(≥ 20%) were grouped and compared to low risk patients 
(<  10%) in the statistical analysis, as the medium-risk 
group had a small numbers of patients. Factors associated 
with medium/high cardiovascular risk were tested by uni-
variate and multivariate analyses. The statistical tests used 
in univariate analysis were the chi-square test, Fisher’s ex-
act test, Student’s t-test, and the Mann-Whitney test. Vari-
ables with p < 0.2 in the univariate analysis were included 
in the multiple logistic regression model. The model was 
subsequently adjusted according to the stepwise backward 
method. The Hosmer and Lemeshow test was used to 
check the fit of the model (p > 0.05). Also, multiple linear 
regression was used to identify factors associated with a 
higher percentage of cardiovascular risk.  
RESULTS
The sample comprised 115 subjects, of which 58.2% were 
males (n = 67). The mean age at evaluation was 52.5 ± 13.1 
years. The average time of transplantation was 56.8 ± 34.7 
months. Regarding schooling, the plurality of the indi-
viduals had not graduated from college/university (39.1%, 
n = 45), high school (26.1%, n = 30), and elementary 
school (26.1%, n = 30). Furthermore, 11.3% (n = 13) of the 
evaluated individuals reported to be illiterate. The general 
characterization of the patients is described in Table 1. 
The most frequent indications for transplantation were 
alcoholic cirrhosis (31.3%, n = 36), cirrhosis due to hepatitis 
C virus (27.8%, n = 32), cirrhosis due to autoimmune hep-
atitis (14.8%, n = 17), cryptogenic cirrhosis (n = 14 12.2%), 
and cirrhosis with hepatocellular carcinoma (7%, n = 8). 
Other indications were observed in 20.9% (n = 24) of cases. 
Family history of hypertension, diabetes mellitus, obe-
sity, and cardiovascular disease were reported by 74.3% 
(n = 84), 49.6% (n = 56), 64.6% (n = 73) and 61.1% (n = 59) 
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Table 2 –  Categorical variables associated with risk of cardiovascular disease > 10% in patients submitted to liver 
transplantation by univariate analysis, according to Framingham score, Belo Horizonte, MG, Brazil, 2011
Parameters
Risk of cardiovascular  disease > 10%
% (n) OR 95% CI p-value
Gender (male x female) 58.2 (39) 29.2 (14) 3.38 1.54-7.45 < 0.01*
Marital status (single x married) 51.3 (40) 35.1 (13) 1.96 0.86-4.34 0.10
Unemployed/retired/homemaker x others 47.9 (35) 42.9 (18) 1.23 0.57-2.64 0.59
Smokers and nonsmokers x former smokers 38.7 (24) 48.7 (19) 1.50 0.67-3.38 0.32
Use of cyclosporine x tacrolimus 69.2 (9) 43.1 (44) 2.94 0.85-10.00 0.08
Transplantation indication due to alcoholic cirrhosis  
× other indications
66.7 (53) 36.7 (13) 3.45 1.50-7.91 < 0.01*
BMI          
BMI prior to liver disease > 25 kg/m² × < 25 kg/m² 59.2 (29) 36.4 (24) 2.54 1.19-5.42 0.01*
BMI prior to liver disease > 30 kg/m² × < 30 kg/m² 81.3 (13) 40.4 (40) 6.39 1.71-23.88 < 0.01*
BMI at evaluation > 25 kg/m² × < 25 kg/m² 53.7 (36) 35.4 (17) 2.12 0.99-4.54 0.05
BMI at evaluation > 30 kg/m² × < 30 kg/m² 58.3 (14) 42.9 (39) 1.87 0.75-4.65 0.18
WC          
WC > 80/90 cm × < 80/90 cm 50.6 (41) 33.3 (11) 2.05 0.88-4.77 0.09
WC > 88/102 cm × < 88/102 cm 52.9 (27) 39.7 (25) 1.71 0.81-3.60 0.16
BMI, body mass index; WC, waist circumference; *p < 0.05, chi-square test.
of patients, respectively. Personal history of overweight 
prior to liver disease was observed in 42.6% (n = 49) of pa-
tients and obesity, in 13.9% (n = 16). At the time of evalua-
tion, the prevalence of overweight was 58.2% (n = 96) and 
of obesity, 20.9% (n = 24) of patients. Abdominal obesity 
was observed in 44.3% (n = 51) patients according to the 
WHO classification, and in 71.1% (n = 82) according to 
the IDF classification. 
According to the Framingham risk score, 53.9% 
(n = 62) patients had low risk for cardiovascular events 
over ten years and 46.1% (n = 53) had medium to high 
risk, of which 16.5% (n = 19) of patients were classified 
as medium and 29.6% (n = 34) as high risk for cardiovas-
cular events in ten years. The mean percentage risk was 
9.5% ± 7.8%. Male gender, older age, indication for trans-
plantation due to alcoholic cirrhosis, overweight, obesity, 
higher BMI prior to liver disease, higher BMI, WC, and 
WHR at the time of assessment were statistically associ-
ated, in the univariate analysis, to a probability higher 
than 10% of coronary events occurring within ten years 
for these patients (Tables 2 and 3). 
Factors that are directly or indirectly associated with 
the calculation of the Framingham score were also associ-
ated with risk in the univariate analysis (glucose, total cho-
lesterol, HDL, and triglycerides), but were not included in 
the multiple or linear logistic regression models. 
The multiple logistic regression model created to 
identify factors independently associated with medium 
and high cardiovascular risk showed a good fit (Hosmer 
and Lemeshow test = 0.88) and resulted in the follow-
ing variables: age (OR: 1.09 CI: 1.04-1.13, p < 0.01), male 
(OR: 4.97 CI: 1.92-12.85, p < 0.01), and BMI at the time of 
evaluation (OR: 1.09, CI: 0.99-1.20, p = 0.09). Variables in-
dependently associated with a higher percentage of cardio-
vascular risk through the multiple linear regression model 
were age (p <  0.01), male sex (p <  0.01), cyclosporine 
use (p = 0.01), and higher body mass index at evaluation 
(p = 0.03). 
DISCUSSION
The Framingham risk score was used in this study as it is 
recommended by the Brazilian Society of Cardiology16 and 
is the standard most often used for stratification of coro-
nary risk worldwide. The estimated risk of cardiovascular 
disease in asymptomatic individuals and the identification 
of associated factors may be useful to classify vulnerable 
groups and allow the development of strategies to prevent 
these problems. However, it is important to emphasize 
that this algorithm has limitations, as it only considers 
traditional risk factors: age, total cholesterol, systolic and 
diastolic blood pressure, diabetes mellitus and smoking 
status. 
Other important risk factors in the epidemiology of 
cardiovascular disease are not considered, such as plasma 
levels of triglycerides and LDL, family history of early car-
diovascular disease, family history of hypertension, BMI 
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Parameter
(mean ± standard deviation)
Patients with  
low risk
Patients with  
medium/high risk
p-value
Age (years) 47.9 ± 14.6 58 ± 8.5 < 0.01*
Time of transplantation (months) 60.0 ± 37.8 50.8 ± 30.4 0.16
Income per capita (R$) 758.32 ± 801.9 953.74 ± 1084.0 0.49
Hours of sleep (per day) 7.71 ± 1.3 7.57 ± 1.4 0.57
Physical activity factor (MET/24) 1.35 ± 0.2 1.3 ± 0.2 0.55
BMI before liver disease (kg/m²) 23.5 ± 3.5 26.9 ± 4.8 < 0.01*
BMI at evaluation (kg/m²) 25.4 ± 4.6 27.6 ± 4.8 < 0.02*
Glucose 89.4 ± 13.4 128.1 ± 56.2 < 0.01*
Total Cholesterol (mg/dL) 161.3 ± 45.1 171.9 ± 40.4 0.19
HDL (mg/dL) 51.2 ± 18.1 44.4 ± 20.6 < 0.01*
Triglycerides (mg/dL) 110.5 ± 49.4 174.7 ± 99.2 < 0.01*
Time of use of prednisone (months) 22.3 ± 30.3 12.4 ± 18.1 0.13
Accumulated dose of prednisone (grams) 6.37 ± 7.28 5.29 ± 6.89 0.77
Waist circumference (cm) 91.4 ± 13.7 99.6 ± 14.2 < 0.01*
Hip circumference (cm) 101.0 ± 10.4 103.8 ± 10.6 0.16
Waist-to-hip ratio (cm) 0.90 ± 0.1 0.96 ± 0.1 < 0.01*
*p < 0.05, Student’s t test and Mann-Whitney test.
Table 3 – Numerical variables associated with the risk of cardiovascular disease > 10% in patients submitted to liver 
transplantation, by univariate analysis, according to Framingham score, Belo Horizonte, MG, Brazil, 2010
(overweight, obesity), abdominal obesity, eating habits, 
and level of physical activity. The cross-sectional design of 
the study is also a limiting factor, as the estimated risk of 
cardiovascular disease development over 10 years was as-
sessed rather than the direct verification of events. 
Another limiting factor was the combination of me-
dium and high risk groups for statistical analysis, as the 
great advantage of scores is their discriminative power. In 
this study, on the one hand, patients in the medium risk 
group could have a similar evolution to that of the patients 
in the low risk group; on the other hand, associating them 
to the low risk group could underestimate their chance of 
developing cardiovascular disease.  
The mean absolute risk of occurrence of a cardiovas-
cular event over the next ten years in the studied sample 
was 9.5%, which is higher than the values reported in the 
literature for the Brazilian population. In a study of 329 ex-
ecutives in São Paulo, Rodrigues and Phillip17 found a low 
probability of occurrence of cardiovascular events  over 
ten years (average risk of 5.7%). Similar values  were also 
found in a study conducted in the state of Amazonas (aver-
age risk of 5.4 to 5.7%, depending on location)18. 
Another study, involving 1,712 individuals aged be-
tween 30 and 59 years residing in Bambuí, state of Minas 
Gerais, also showed low cardiovascular risk (more than 
half of the population did not exceed the 5% risk)19. The 
data found in the present study population are in agree-
ment with the mean values  of cardiovascular risk described 
in populations submitted to liver transplantation – 7.9% in 
the study by Johnston et al.9 and 11.5% in the study by Neal 
et al.20, supporting the premise that these patients have 
higher risk of developing cardiovascular disease.
The mean risk found (9.5%) is very close to the value of 
10% (considered intermediate risk); nearly half the stud-
ied population (46.1%) showed medium to high risk, and 
of these, approximately 30% were classified as high risk. 
Therefore, these results emphasize the need for interven-
tion measures proposed in the last Brazilian guideline on 
dyslipidemia and atherosclerosis prevention16.  
The level of physical activity and categorization of 
patients as sedentary, low active, and active were not as-
sociated with cardiovascular risk in this study. Although 
low levels of physical activity and a sedentary lifestyle are 
classic risk factors for cardiovascular disease16, it should 
be noted that the calculation of the daily physical activ-
ity level had limitations, as the time available for detailed 
descriptions of daily activities at the time of data collection 
was short. Furthermore, the calculation was made based 
on the activities performed by that patient at the time of 
the data collection, and thus, it may not reflect the entire 
period of time elapsed from transplantation (or since liver 
disease limited the daily activities and reduced the level of 
daily physical activities) to the date of evaluation. 
In the present study, male gender, older age, and higher 
BMI at the time of evaluation were considered predictive 
factors for medium and high risk of cardiovascular events 
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in the population undergoing liver transplantation. It is 
known that cardiovascular disease mortality is higher in 
males, when compared to females, at all circumstances and 
all age ranges, and that the occurrence of events increases 
progressively with age21. The higher incidence of cardio-
vascular disease in males compared to females of similar 
ages has been attributed not only to gender differences re-
lated to sexual hormones, but also to differences in cell and 
vascular tissue that mediate specific sexual responses22. 
Moreover, a higher score in the Framingham risk score is 
attributed to both older age and male sex. However, the 
permanence of these variables in the model would help to 
eliminate confounding factors. 
In the studied population, BMI was the anthropomet-
ric measure most often related to higher incidence of car-
diovascular events. The results showed that a higher BMI 
at the time of assessment tended to show statistical signifi-
cance (p = 0.09) in the multivariate analysis as an indepen-
dent factor for cardiovascular risk.
On the other hand, the removal of this variable would 
negatively impact the fit of the model and thus, it was kept 
in the analyses. The association between the degree of obe-
sity and the incidence of cardiovascular events has been 
well described in the literature23-24.
It has been know for some time that weight gain after 
adulthood results in an increased risk of cardiovascular 
disease in both genders25. Overweight and obesity are also 
indicated in the population undergoing liver transplan-
tation as related to cardiovascular risk6,11. The WC and 
WHR were associated with increased likelihood of devel-
oping cardiovascular events only in the univariate analysis. 
Although the BMI at the time of evaluation was the best 
predictor of cardiovascular risk, WC and WHR measure 
the amount of central adipose tissue, which is more meta-
bolically active than peripheral fat tissue, thus implying in 
a higher risk factor for metabolic syndrome, insulin ac-
tion resistance and cardiovascular disease in the general 
population26,27. A high BMI reflects a great mass of adipose 
tissue, which, especially when it is visceral, influences the 
regulation of adipokines. 
Adiponectin is an anti-inflammatory adipokine (it an-
tagonizes the development of atherosclerosis and vascular 
inflammation), which shows decreased serum concentra-
tions in obese individuals. Serum concentrations of leptin, 
which controls food intake, are increased in these individ-
uals influencing the energy balance and compromising the 
immune response.  
The evidence suggests that leptin increases blood pres-
sure and sympathetic nerve activity, stimulates the genera-
tion of reactive oxygen species, induces platelet aggrega-
tion, and promotes arterial thrombosis, being considered 
an independent risk factor for cardiovascular disease. In 
addition, resistin expression in adipocytes is reduced but 
it is high in macrophages and monocytes, suggesting an 
important role in inflammation. Resistin levels are el-
evated in obese individuals and, therefore, are linked with 
obesity-related insulin resistance. Resistin has a high ath-
erogenic action by increasing the expression of intercellu-
lar adhesion molecules. Concomitantly, there is increased 
secretion of proinflammatory cytokines that collectively 
damage the endothelium, stimulating inflammatory/pro-
liferative reaction in the vascular wall28.
In addition to increased BMI, patients classified as hav-
ing medium/high risk had significantly higher triglycer-
ides and glucose levels and lower HDL levels. These find-
ings suggest that these patients have a higher prevalence 
of metabolic syndrome than low risk patients. Metabolic 
syndrome is described in approximately half of patients 
undergoing liver transplantation29, and has also been de-
scribed as a risk factor for cardiovascular disease in this 
population30, as well as in the general population31. These 
results were expected, as triglycerides, glucose, and HDL 
are part of the Framingham score, either directly or 
indirectly. 
The multiple linear regression analysis demonstrated 
that the use of cyclosporine, at the expense of the use of 
tacrolimus, was associated with greater percentage of risk 
of cardiovascular events. Other studies also showed this 
association32-33. 
This fact can be explained by the influence of this drug 
on blood pressure, and cyclosporine is considered to be 
more hypertensive than tacrolimus6,20,32. Although these 
results are in agreement with literature data, it is important 
to note that, at the moment of the evaluation, few patients 
were taking cyclosporine (11.3%, n = 13), as the current 
immunosuppression protocol for transplants where the 
study was carried out is based on the use of tacrolimus.
Based on the results, it can be concluded that the risk of 
incidence of cardiovascular events over the next ten years 
in patients undergoing liver transplantation is higher than 
that of the general Brazilian population. These aspects in-
dicate the need for greater attention of multidisciplinary 
teams involved in the care of these patients. These patients 
should be introduced early into lifestyle modification pro-
grams, especially male and older individuals.
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